单唾液酸四己糖神经节苷脂辅助治疗急性颅脑损伤的疗效及安全性

Curative Effect and Safety of Monosialoganglioside for Adjunctive Therapy in Acute Craniocerebral Injury Treatment

目的:探讨单唾液酸四己糖神经节苷脂辅助治疗急性颅脑损伤的疗效与安全性。方法:急性颅脑损伤患者284例随机分为对照组(142例)和观察组(142例)。两组均行常规综合治疗,观察组同时加用注射用单唾液酸四己糖神经节苷脂钠40 mg qd。疗程均为3周。观察两组患者治疗前后的格拉斯哥错迷评分(GCS)、神经功能缺损评分、Barthel指数量表评分,以及血压、心率、颅内压脑血肿体积变化,比较两组疗效与药物不良反应。结果:治疗后,观察组心率、血压异常发生率明显低于对照组(P<0.05),颅内压情况明显优于对照组(P<0.05)。两组治疗后GCS评分、神经功能缺损评分及Barthel指数评分均有所改善(P<0.05),且观察组各项指标评分均显著高于对照组(P<0.05)。两组脑血肿体积均显著减小(P<0.05)且观察组脑血肿体积显著小于对照组(P<0.05)。观察组总有效率为83.80%,明显高于对照组的66.90%(P<0.05)。两组药品不良反应发生率差异无统计学意义(P>0.05)。结论:急性颅脑损伤患者常规治疗基础上加用单唾液酸四己糖神经节苷,可明显改善患者神经功能,降低颅内压,提高治疗有效率。

Objective： To study the effect and safety of using monosialoganglioside for adjunctive therapy in acute craniocerebral injury treatment. Methods： 284 patients with acute craniocerebral injury in our hospital were selected and randomly divided into control group（ 142 cases） and observation group（ 142 cases）. Both groups received the routine combined treatment,while the observation group also continued to take monosialoganglioside 40 mg · d^（-1） at the meantime.Treatment was 3 weeks for both groups. The GCS score,neural function defect scale,Barthel index rating scale,and the change of blood pressure,heart rate,intracranial pressure,cerebral hematoma volume of two groups were obseved before and after treatment. The curative effect and adverse drug reactions were also campared. Results： After the treatment,the incidence of abnormal heart rate changes and blood pressure in the observation group were significantly lower than that in the control group（ P〈0. 05）,the intracranial pressure in the observation group was better than that in the control group（ P〈0. 05）. The GCS,the neural function defect scale and the Barthel index score after treatment was improved（ P〈0. 05）.And the indicators in observation group were significantly higher than that in control group respectively,with statistical difference（ P〈0. 05）. The volume of brain hematoma was significantly decreased（ P〈0. 05）,and the volume of brain hematoma in observation group was significantly less than that in control group respectively,with statistical difference（ P〈0. 05）. The total efficacy rates of the observation group was 83. 80%,which was higher that in the control group（ P〈0. 05）. The incidence of adverse drug reactions between the two groups had no statistical significance（ P〉0. 05）. Conclusion： For patients with acute craniocerebral injury,monosialoganglioside used on the basis of conventional treatment could significantly improve neurological function in patients,reduced the intracranial pressure,and improve treatment efficiency.